New findings indicate that Elenagen, when combined with gemcitabine, significantly extends overall survival in patients battling platinum-resistant ovarian cancer. Data from a Phase II randomized study reveals a notable reduction in mortality risk, with no increase in toxicity.
Platinum-resistant ovarian cancer presents a significant therapeutic challenge. Elenagen, a DNA-based anticancer agent, targets the p62 sequestosome one protein, influencing cellular processes like autophagy and inflammation.
The study involved 30 patients randomly assigned to receive either gemcitabine alone or gemcitabine plus Elenagen weekly. For patients with elevated cancer antigen 125 levels, median overall survival in the combination arm reached 25 months, compared to 13 months with gemcitabine alone. Treatment with Elenagen reduced the risk of death by 59%.
Further analysis indicated a strong correlation between longer Elenagen exposure and improved survival outcomes, suggesting a dose-response effect. Importantly, the addition of Elenagen did not introduce new safety concerns.
These results support Elenagen as a promising therapeutic strategy for platinum-resistant ovarian cancer, warranting further investigation.